Stockreport

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

CG Oncology, Inc. - Common stock  (CGON) 
PDF - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Canc [Read more]